Supplemental materials for study "Impact of the methotrexate co-prescription on the persistence of TNF inhibitors in psoriasis: a cohort study on the French National Health Data System"

This supplemental material provides additional methodological details, definitions, and results supporting the main analysis.

Data Source: Describes the French national health data system (SNDS), and approvals for study.

Marginal Structural Models (MSMs) with Inverse Probability of Treatment Weighting (IPTW) and Inverse Probability of Censoring Weighting (IPCW): Provides a detailed explanation of the statistical modeling framework used to estimate the causal effect of concomitant methotrexate (MTX) on TNFi persistence, including model specification, weight construction, stabilization, and truncation procedures.

Contents
Data source
Marginal Structural Models (MSMs) with Inverse Probability Treatment Weighting (IPTW) and Inverse Probability Censoring Weighting (IPCW)
Supplemental Table I. Definition of medicine exposures
Supplemental Table II. Algorithms to identify comorbidities
Supplemental Table III. Population baseline characteristics across methotrexate exposure levels
Supplemental Table IV. Continuous and categorical concomitant methotrexate use across dosing regimes and calculation methods over trimesters
Supplemental Table V. Impact of concomitant methotrexate on TNFi persistence: sensitivity analyses. 15
Supplemental Table VI. Impact of concomitant methotrexate on adalimumab persistence: post-hoc subgroup analysis.
Supplemental Figure 1. Directed acyclic graph showing the association among biologic persistence, concomitant methotrexate, and time-varying covariates.